Fondazione Italiana Diabete ETSFondazione Italiana Diabete ETS
Understanding why type 1 diabetes develops is the key to one day preventing it and ultimately achieving a definitive cure.
With this objective, the FID-INNODIA Grant has been established: an international funding programme promoted by Fondazione Italiana Diabete ETS (FID) in partnership with INNODIA, an international non-profit organisation with the mission to accelerate the development of therapies that can transform the lives of people with Type 1 Diabetes (T1D) and improve access to approved treatments
The Grant supports one independent research project using the INNODIA Data & Samples Collection, one of the most extensive European longitudinal data and biological samples collection.
The FID-INNODIA Grant is open to independent researchers affiliated with universities, hospitals, or research centres (private companies are not eligible) and aims to promote innovative studies on the pathogenesis and mechanisms underlying the development of type 1 diabetes, through the data and biological samples made available by INNODIA.
FUNDING
The funding is awarded to the researcher’s institution and may cover personnel and research materials. The maximum allowable overhead is 8%.
TYPES OF DATA AVAILABLE
The selected project will have access to the INNODIA Data & Samples Collection which includes pseudonymised data and samples collected within the framework of the European INNODIA projects from individuals newly diagnosed (ND) with Stage 3 T1D (monitored for up to 2 years) and from unaffected family members (UFM) tested for IAb and monitored after IAb detection
As specified in the Data Use Agreement (DUA) available datasets include:
Access to the data is subject to approval by the INNODIA Data Access Committee (DAC) and governed by the Data Use Agreement (DUA).
CORE PRINCIPLES:
TIMELINE
Call opens: 2 March 2026
Submission deadline: 4 May 2026
Evaluation Timeline
EVALUATION PROCESS
Applications will undergo a two-step evaluation process:
Conducted by the INNODIA Data Access Committee (DAC), which verifies that:
Conducted by the FID Scientific Committee, which performs peer review and proposes the winning project to the Board of Directors for final ratification.
ELIGIBILITY
Applicants must be:
REQUIRED DOCUMENTATION
Applications must include:
OBLIGATIONS OF THE GRANT RECIPIENT
As with all FID Grants and INNODIA initiatives, the FID-INNODIA Grant requires the active involvement of people living with Type1 Diabetes.
Within the “Allies for the Cure” initiative (link), the selected researcher will collaborate with an FID volunteer certified as an INPACT Associate, who will support:
At least three meetings are required over the course of the research project.
The Grant recipient undertakes to:
Completion of the online form constitutes the official application to the FID-INNODIA Grant 2026
FID and INNODIA have opened the FID-INNODIA Grant to co-funding by patient organisations, foundations, and other non-profit entities, with the aim of expanding the impact of the call and funding a greater number of high-quality research projects.
Many organisations wish to actively support research into type 1 diabetes but may not have:
Through the FID-INNODIA Grant, these organisations can contribute to research within a rigorous, transparent, and fully established framework that guarantees scientific excellence, administrative compliance, and continuous oversight.
Minimum contribution: €10,000
Co-funding contributions may:
FID’s annual €50,000 contribution remains unchanged.
To participate in the 2026 call, organisations must:
For all enquiries and communications:
📩 francesca.ulivi@fondazionediabete.org
Dual Scientific Evaluation
Monitoring and Reporting
Funded projects are subject to:
Transparent Communication
FID and INNODIA coordinate all communications related to the Grant, ensuring:
Co-funding the FID-INNODIA Grant enables organisations to:
It is a concrete and measurable way to turn commitment into impact.